The Allegations: Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo's Phase 3 CagriSema Study on Obesity According to the complaint ...

On 21 December of last year, the Danish pharmaceutical company experienced a 21% plunge in its share price following disappointing trial results for its new obesity drug, CagriSema. Amycretin is ...

Investors had dumped Novo shares in late December when data on a highly touted experimental Novo weight-loss shot called CagriSema fell far short of the expectations the company had set.

Twice in the past two months, investors have been disappointed by the numbers -- 22.7% average weight loss over 68 weeks for CagriSema, and 20.7% weight loss for a 72-week regimen of semaglutide 7 ...

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

In late December, Novo Nordisk announced that its much anticipated next-generation obesity drug CagriSema had missed its target for patients to lose 25 per cent of their body weight in a late ...

Novo’s CagriSema is a once-a-week injection that combines cagrilinitide, a novel amylin analog, with semaglutide. Amylin analogs slow down the rate at which food empties from the stomach into ...

Novo is already licking its wounds from another setbackits experimental two-drug combo, CagriSema, underwhelmed in trials, landing at 22.7% weight loss, barely moving the needle against Zepbound.

Novo also could have other diabetes and obesity drugs on the way, notably including late-stage candidate CagriSema. Also, President Trump has promised to repeal the IRA -- primarily because he ...

News of price negotiations followed a stock market bloodbath in December when Novo Nordisk lost €90 billion in value when its latest weight loss drug, CagriSema, failed to hit a predicted 25% ...

after last year's disappointing trial study of the next-generation CagriSema drug. They rate the stock a buy with a $110 price target for the U.S.-listed shares.